SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QuestCor QSC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: roy whitt who wrote (64)12/11/1997 8:47:00 AM
From: gcrispin  Read Replies (1) of 120
 
It should not go unnoticed that the largest shareholder in CYPR is Harvard University. The second largest shareholder is Paul Marangos, the CEO, and the third is Bernie Levine, who helped bring the company public. The company has had a checkered past in terms of its dealings with the financial community. Nevertheless, this is a company that has completed three phase two trials on CPC-111 and Ceresine. Paul Marangos has purposely kept the company small to conserve cash. There are only thirty plus employees. He has also purchased a collection of acute-care drugs that he believes will grow in sales, and, consequently, reduce the burn rate of the company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News